


conferenceseries.com

946th Conference

Scientific Program

Proceedings of

7th European Biosimilars Congress

May 15-16, 2017 Munich, Germany

Conference Series - America

One Commerce Center-1201, Orange St. #600, Wilmington,
Zip 19899, Delaware, USA
P: +1-702-508-5200, F: +1-650-618-1417

Conference Series - UK

Kemp House, 152 City Road, London EC1V 2NX, UK
Toll Free: +1-800-014-8923

Day 1 May 15, 2017

09:30-10:00 Registrations

Lilli Palmer

conferenceseries.com 10:00-10:10 **Opening Ceremony**

Keynote Forum

10:10-10:15 Introduction

10:15-11:05 Title: The commercial landscape for biosimilars: Planning in an uncertain environment
Arthur G. Cook, ZS Associates, USA

Networking & Refreshment Break 11:05-11:30 @ Breakout Area

11:30-12:20 Title: Intellectual property and regulatory interplay in biosimilars
Christoph Volpers, Michalski Hüttermann & Partner, Germany

Group Photo 12:20-12:35 @ Breakout Area

Lunch Break 12:35-13:35 @ Restaurant

Sessions: Innovative Approach for Biosimilars | Clinical Development of Biosimilars | Emerging Biosimilars in Therapeutics

Session Chair: Tim Demuth

Session Introduction

13:35-14:15 Title: CMC considerations for biosimilar drug development
Ulrike Konrad, Karl Ruprecht Universität, Germany

14:15-14:55 Title: Search for unknown immunogenicity: An overview
Rosa Helena Bustos, University of La Sabana, Colombia

Networking & Refreshment Break 14:55-15:25 @ Breakout Area

15:25-16:05 Title: Development of Etanercept biosimilar Erelzi™
Tim Demuth, Sandoz, Germany

16:05-16:45 Title: Development and *in-vivo* evaluation of Ofloxacin gastro-retentive drug delivery system
Dina E Abo Elezz, Pharos University, Egypt

Panel Discussion

Day 2 May 16, 2017

Lilli Palmer

Keynote Forum

10:10-10:15 Introduction

10:15-11:05 Title: How AbbVie tries to fend off world's blockbuster No 1 from generic competition
Ulrich Storz, Michalski Hüttermann & Partner, Germany

Networking & Refreshment Break 11:05-11:25 @ Breakout Area

11:25-12:25 Title: Innovative, cost effective solution for self-administration of Bio-similar drugs
Tsachi Shaked, E3D Elcam Drug Delivery Devices, Israel
Menachem Zucker, E3D Elcam Drug Delivery Devices, Israel

Lunch Break 12:25-13:25 @ Restaurant

Sessions: Biosimilar Market and Cost Analysis | Analytical Strategies for Biosimilars | Globalization of Biosimilars

Session Chair: Tim Demuth

Session Introduction

13:25-14:05 Title: Evidence-based approach of CT-P13 to meet the expectations of different stakeholders
Stanley Seung Suh Hong, Celltrion Healthcare Co. Ltd., South Korea

14:05-14:45 Title: Multilevel characterization of biosimilars by CE-LIF and CE-MS
Andras Guttman, University of Pannonia, USA

14:45-15:25 Title: Development of a methodology for the evaluation of tumor necrosis factor antibody (anti-TNF-alpha) in patients with treatment of biological products through the use of Nanobiosensors
Efraín Esteban, University of La Sabana, Colombia

15:25-16:05 Title: Study of liver toxicity and its reversibility of Cassytha filiformis defatted ethanolic extract on mice
Armenia Nazar, University of Andalas, Indonesia

Networking & Refreshment Break 16:05-16:30 @ Breakout Area

Poster Presentations 16:30-17:30 @ Meeting Halls

Award Ceremony